ERBB2 and non-small cell lung carcinoma: Further, Ado-trastuzumab emtansine (T-DM1), which is another ADC composed of trastuzumab linked to emtansine (an anti-microtubule agent) (DM1), has been proven to show a prominent efficacy in patients with Her2 mutation-positive NSCLC, particularly those with exon-20 insertion mutations [56].